AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Disorders: Piperidolate hydrochloride is commonly prescribed to alleviate symptoms associated with gastrointestinal disorders characterized by smooth muscle spasms, such as irritable bowel syndrome (IBS), functional dyspepsia, and gastric hyperacidity. It helps reduce abdominal pain, cramping, and discomfort by relaxing the smooth muscles of the gastrointestinal tract.
Urinary Tract Disorders: Piperidolate hydrochloride may be used to relieve symptoms of urinary tract disorders, including urinary urgency, frequency, and dysuria, associated with conditions such as urinary tract infections (UTIs) or interstitial cystitis. By exerting its antispasmodic effects on the smooth muscles of the urinary bladder, it can help reduce bladder spasms and alleviate urinary symptoms.
Biliary Disorders: In conditions like biliary colic or cholecystitis, where there are spasms in the bile ducts or gallbladder, piperidolate hydrochloride may be prescribed to alleviate pain and discomfort by relaxing the smooth muscles of the biliary tract.
Gynecological Disorders: Piperidolate hydrochloride may be used as an adjunctive treatment for gynecological disorders characterized by uterine or pelvic muscle spasms, such as dysmenorrhea (menstrual cramps) or endometriosis. It can help reduce pelvic pain and discomfort associated with these conditions.
Smooth Muscle Spasms: Piperidolate hydrochloride's antispasmodic properties make it effective in relieving smooth muscle spasms in various parts of the body, including the gastrointestinal tract, urinary bladder, biliary system, and reproductive organs.
Diagnostic Procedures: In some cases, piperidolate hydrochloride may be used to reduce smooth muscle contractions during diagnostic procedures such as gastrointestinal endoscopy or cystoscopy, where muscle relaxation is necessary for optimal visualization and procedural success.
Preoperative Medication: Piperidolate hydrochloride may be administered preoperatively to patients undergoing certain surgical procedures involving the gastrointestinal or genitourinary systems to reduce muscle spasms and facilitate surgical access.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1 | 0.3 | 2.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.7 | 0 |
| Allergies | 1.4 | 1.8 | -0.29 |
| Allergy to milk products | 0.9 | 0.4 | 1.25 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2 | 0.9 | 1.22 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.9 | 0.22 |
| Ankylosing spondylitis | 1.6 | 0.6 | 1.67 |
| Anorexia Nervosa | 1 | 0.9 | 0.11 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.1 | 1.3 | -0.18 |
| Atherosclerosis | 0.3 | 0.4 | -0.33 |
| Atrial fibrillation | 1.3 | 0.4 | 2.25 |
| Autism | 2.7 | 3 | -0.11 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1 | 0.6 | 0.67 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.3 | -0.3 | |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 0.3 | 1.4 | -3.67 |
| Cerebral Palsy | 0.7 | 0.3 | 1.33 |
| Chronic Fatigue Syndrome | 1.8 | 1.5 | 0.2 |
| Chronic Kidney Disease | 0.7 | 0.7 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
| Chronic Urticaria (Hives) | 0.3 | 0.6 | -1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.6 | 0.17 |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 2.7 | 2.7 | |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.6 | 0.6 | |
| COVID-19 | 2.6 | 2.6 | 0 |
| Crohn's Disease | 2.3 | 2.1 | 0.1 |
| deep vein thrombosis | 0.7 | 0.6 | 0.17 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 3.6 | 3.2 | 0.13 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.4 | -0.33 |
| Endometriosis | 0.7 | 0.6 | 0.17 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.7 | 1.7 | -1.43 |
| Fibromyalgia | 1 | 1 | |
| Functional constipation / chronic idiopathic constipation | 1.3 | 0.7 | 0.86 |
| gallstone disease (gsd) | 0.7 | 0.4 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 1 | 0.7 | 0.43 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.7 | 0.43 |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.3 | 1 | -2.33 |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.7 | 0.7 | 0 |
| Heart Failure | 1.1 | 0.7 | 0.57 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.6 | -0.6 | |
| hyperglycemia | 0.7 | 1.4 | -1 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
| hypertension (High Blood Pressure | 2.6 | 1.1 | 1.36 |
| Hypothyroidism | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.8 | 0.8 | |
| IgA nephropathy (IgAN) | 1.3 | 0.1 | 12 |
| Inflammatory Bowel Disease | 1.9 | 3 | -0.58 |
| Insomnia | 0.4 | 1.9 | -3.75 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.6 | 2.3 | -0.44 |
| ischemic stroke | 1.4 | 1.4 | |
| Liver Cirrhosis | 1.8 | 2.2 | -0.22 |
| Long COVID | 1.7 | 2 | -0.18 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.9 | -0.9 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.3 | 0.3 | |
| ME/CFS without IBS | 1 | 0.6 | 0.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.4 | -0.33 |
| Metabolic Syndrome | 1.7 | 2 | -0.18 |
| Mood Disorders | 4.2 | 2.9 | 0.45 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 2.8 | 1.7 | 0.65 |
| Multiple system atrophy (MSA) | 1 | 0.3 | 2.33 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | 1.1 | -2.67 |
| Neuropathy (all types) | 1 | 0.4 | 1.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 1.6 | -0.78 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.9 | |
| Obesity | 3.5 | 3.3 | 0.06 |
| obsessive-compulsive disorder | 1.5 | 0.9 | 0.67 |
| Osteoarthritis | 0.3 | 1 | -2.33 |
| Osteoporosis | 0.6 | 0.9 | -0.5 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 3.2 | 0.9 | 2.56 |
| Polycystic ovary syndrome | 2.4 | 1.5 | 0.6 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.7 | 1.3 | -0.86 |
| Psoriasis | 1 | 1.6 | -0.6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 2.5 | |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 2.2 | 1.4 | 0.57 |
| scoliosis | 0.4 | -0.4 | |
| Sjögren syndrome | 0.7 | 0.4 | 0.75 |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.8 | 1.5 | -0.88 |
| Systemic Lupus Erythematosus | 1 | 0.6 | 0.67 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.7 | 0.7 | |
| Type 1 Diabetes | 1.2 | 0.9 | 0.33 |
| Type 2 Diabetes | 1.7 | 2 | -0.18 |
| Ulcerative colitis | 1 | 1.7 | -0.7 |
| Unhealthy Ageing | 0.6 | 0.8 | -0.33 |
| Vitiligo | 1.3 | 0.8 | 0.63 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
